Questionnaire survey of the tolerance and undesirable effects of clodronate (Bonefos) in patients with multiple myeloma;Dotazníkový průzkum tolerance a nežádoucích účinků klodronátu (preparátu Bonefos) u pacientů s mnohočetným myelomem

Vnitrni Lekarstvi

Volumn 48, Issue 11, 2002, Pages 1049-1053

  Lastuvkova I ^a   Adam, Z ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Bisphosphonates; Clodronate; Multiple myeloma

Indexed keywords

CLODRONIC ACID; CYTOSTATIC AGENT;

ARTICLE; CALCIUM INTAKE; CAPSULE FILLING; CONTROLLED STUDY; CZECHOSLOVAKIA; DRUG INDUCED DISEASE; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PARESTHESIA; QUESTIONNAIRE; TREATMENT INDICATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; ADULT; AGED; CLODRONIC ACID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; QUESTIONNAIRES;

EID: 0036439622     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Adam, Z., Prokeš, B., Znojil, V. et al.: Vliv klodronátu na kostní denzitu pacientu s mnohočetným myelomem. Dvouleté sledování léčebného účinku. Vnitř. Lék., 42, 1996, 6, 379-385
2. Fleisch, H.: Bisphosphonate in Bone Disease. Academic press, San Diego, San Francisco, 2000, 212 s.
3. Heim, M. E., Clemens, M. R., Queisser, W. et al.: Prospective randomized trial of dichlormethylene bisphosphonate clodronate in patients with multiple myeloma requiring treatment. Onkologie, 18, 1995, 439-448
4. Johnson, M. J.: Symptomatic hypocalcemia with oral clodronate. J. Pain Symptom Manage, 15, 1998, 2, 140-142
5. Lahtinen, R., Laakso, M., Palva, I. et al.: Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, 340, 1992, 8827, 1049-1052
6. Laitinen, K., Patronen, A., Harju, P. et al.: Timing of food intake has a marked effect on the bioavailability of clodronate. Bone, 26, 2000, 3, Suppl., 38, abstr. B39
7. McCloskey, E. V., Dunn, J. A., Kanis, J. A. et al.: Long-term follow-up of a prospective, double blind, placebo controlled randomized trial of clodronate in multiple myeloma. Brit. J. Haematol., 113 (4), 2001, 1035-1043
8. McCloskey, E. V., MacLennan, I. C. M., Drayson, M. et al.: A randomized trial of the effect of clodronate on skeletal morbitidy in multiple myeloma. Brit. J. Haematol., 100, 1998, 317-325
9. McCloskey, E. V., MacLennan, I. C. M., Drayson, M. et al.: Effect of clodronate on morbidity and mortality in myelomatosis. Ann. Oncol., 7, 1996, Suppl. 5, Abstr. c. 4120
10. Peest, D., Deicher, H., Fett, W. et al.: Pyridinium cross-links in multiple myeloma: Correlation with clinical parameters and use for monitoring of intravenous clodronate therapy. A pilot study of the German Myeloma Treatment Group. Eur. J. Cancer, 32A, 1996, 12, 2053-2057
11. Saha, H., Castren-Kortekangas, P., Ojanen, S. et al.: Pharmacokinetics of clodronate in renal failure. J. Bone Mineral Research, 9, 1994, 12, 1953-1958
12. Shipman, C. M., Rogers, M. J., Apperley, J. F. et al.: Bisphosphonates include apoptosis in human myeloma cell lines. A novel anti-tumour activity. Brit. J. Haematol., 98, 1997, 3, 665-672
13. Slabý, J., Klener, P.: Acidum clodronicum. Remedia, 4, 1994, 3, 161-165
14. Tomíška, M., Adam, Z., Prokeš, B. et al.: Bone mineral density in multiple myeloma patients after intravenous clodronate therapy. Acta Medica Austriaca, Heft 2, 2001, 38-43
15. Vorlíček, J., Vyzula, R., Adam, Z.: Praktická Onkologie - Vybrané kapitoly. Praha, Grada publishing, 2000, 340 s.